Literature DB >> 2526150

Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.

K J Pettersson1, T Nordgren, D Westerlund.   

Abstract

Bioanalytical liquid chromatographic methods for the determination of phosphonoformate (foscarnet) have been developed. Biological fluids, after simple pre-treatment (ultrafiltration and/or treatment with charcoal), were injected into a reversed-phase liquid chromatographic system with electrochemical detection. Foscarnet was retained as an ion pair with tetrahexylammonium; addition of pyrophosphate was necessary in order to obtain an acceptable peak. This additive could also be used for the fine regulation of the retention to achieve the necessary selectivity.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2526150     DOI： 10.1016/s0378-4347(00)82968-0

Source DB:  PubMed          Journal:  J Chromatogr


  14 in total

1.  Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits.

Authors:  L F López-Cortés; R Ruiz-Valderas; M J Lucero-Muñoz; E Cordero; M T Pastor-Ramos; J Marquez
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Authors:  A M Taburet; C Katlama; C Blanshard; G Zorza; D Gazzard; E Dohin; B G Gazzard; C Frostegard; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.

Authors:  F H Noormohamed; M S Youle; C J Higgs; S Martin-Munley; B G Gazzard; A F Lant
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.

Authors:  M A Jacobson; B Polsky; D Causey; R Davis; W Tong; J J O'Donnell; B D Kuppermann; M H Heinemann; J Feinberg; P Lizak
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Penetration of foscarnet into cerebrospinal fluid of AIDS patients.

Authors:  F Raffi; A M Taburet; B Ghaleh; A Huart; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.

Authors:  U R Hengge; N H Brockmeyer; R Malessa; U Ravens; M Goos
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  Drug binding by reservoirs in elastomeric infusion devices.

Authors:  D R Jenke
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

8.  Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet.

Authors:  R Schvarcz; B G Hansson; J O Lernestedt; O Weiland
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

9.  Foscarnet for suppression of human immunodeficiency virus replication.

Authors:  C V Fletcher; A C Collier; F S Rhame; D Bennett; M F Para; C C Beatty; C E Jones; H H Balfour
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

Authors:  J Sjövall; S Bergdahl; G Movin; S Ogenstad; M Saarimäki
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.